Pulse Biosciences (PLSE) Lifted to “Hold” at ValuEngine

Pulse Biosciences (NASDAQ:PLSE) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Friday.

Separately, BidaskClub cut Pulse Biosciences from a “hold” rating to a “sell” rating in a report on Friday, December 22nd.

Pulse Biosciences (NASDAQ PLSE) traded up $0.80 during mid-day trading on Friday, reaching $19.76. 114,317 shares of the company’s stock were exchanged, compared to its average volume of 86,400. Pulse Biosciences has a 12 month low of $6.62 and a 12 month high of $39.50. The firm has a market capitalization of $322.90, a PE ratio of -14.22 and a beta of -0.17.

Pulse Biosciences (NASDAQ:PLSE) last issued its earnings results on Tuesday, November 7th. The company reported ($0.52) EPS for the quarter.

In related news, Director Maky Zanganeh purchased 4,000 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was purchased at an average price of $23.07 per share, for a total transaction of $92,280.00. Following the acquisition, the director now directly owns 332,500 shares in the company, valued at $7,670,775. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.70% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PLSE. Nationwide Fund Advisors acquired a new stake in Pulse Biosciences during the 2nd quarter worth about $177,000. The Manufacturers Life Insurance Company bought a new stake in Pulse Biosciences in the 2nd quarter valued at about $250,000. California Public Employees Retirement System bought a new stake in Pulse Biosciences in the 2nd quarter valued at about $297,000. OxFORD Asset Management LLP bought a new stake in Pulse Biosciences in the 2nd quarter valued at about $310,000. Finally, Rhumbline Advisers bought a new stake in Pulse Biosciences in the 2nd quarter valued at about $325,000. Hedge funds and other institutional investors own 9.31% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/04/pulse-biosciences-plse-lifted-to-hold-at-valuengine.html.

About Pulse Biosciences

Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply